Recent optimization of advanced techniques for quantitative protein measurements demonstrated that CSF and serum neurofilament light chain (sNfL) concentrations in MS patients are highly correlated, thus sNfL measurements are rapidly gaining traction as a potential biomarker for MS in numerous studies and clinical trials [7,8]. The gene discussed is NEFL; the disease is myeloid sarcoma.